NasdaqGM:IOVA

Stock Analysis Report

Executive Summary

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells.

Rewards

Trading at 67.7% below its fair value

Risk Analysis

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year



Snowflake Analysis

Flawless balance sheet and slightly overvalued.

Share Price & News

How has Iovance Biotherapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: IOVA has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-0.2%

IOVA

1.1%

US Biotechs

1.7%

US Market


1 Year Return

153.5%

IOVA

11.3%

US Biotechs

23.6%

US Market

Return vs Industry: IOVA exceeded the US Biotechs industry which returned 10.9% over the past year.

Return vs Market: IOVA exceeded the US Market which returned 24.7% over the past year.


Shareholder returns

IOVAIndustryMarket
7 Day-0.2%1.1%1.7%
30 Day-18.8%0.2%3.5%
90 Day15.8%19.5%11.7%
1 Year153.5%153.5%12.3%11.3%26.2%23.6%
3 Year233.9%233.9%29.2%24.9%53.2%43.3%
5 Year165.3%165.3%3.7%-1.2%75.5%56.1%

Price Volatility Vs. Market

How volatile is Iovance Biotherapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Iovance Biotherapeutics undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: IOVA ($24.34) is trading below our estimate of fair value ($75.27)

Significantly Below Fair Value: IOVA is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: IOVA is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: IOVA is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate IOVA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: IOVA is overvalued based on its PB Ratio (8.7x) compared to the US Biotechs industry average (3.2x).


Next Steps

Future Growth

How is Iovance Biotherapeutics forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

43.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: IOVA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: IOVA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: IOVA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if IOVA's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if IOVA's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if IOVA's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Iovance Biotherapeutics performed over the past 5 years?

-36.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: IOVA is currently unprofitable.

Growing Profit Margin: IOVA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: IOVA is unprofitable, and losses have increased over the past 5 years at a rate of -36.7% per year.

Accelerating Growth: Unable to compare IOVA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IOVA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (103.3%).


Return on Equity

High ROE: IOVA has a negative Return on Equity (-46.91%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Iovance Biotherapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: IOVA's short term assets ($367.3M) exceed its short term liabilities ($34.6M).

Long Term Liabilities: IOVA's short term assets ($367.3M) exceed its long term liabilities ($6.1M).


Debt to Equity History and Analysis

Debt Level: IOVA is debt free.

Reducing Debt: IOVA had no debt 5 years ago.


Balance Sheet

Inventory Level: IOVA has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if IOVA's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IOVA has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: IOVA has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of -41.8% each year.


Next Steps

Dividend

What is Iovance Biotherapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.1%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate IOVA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate IOVA's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IOVA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IOVA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IOVA's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Iovance Biotherapeutics's salary, the management and board of directors tenure and is there insider trading?

3.0yrs

Average management tenure


CEO

Maria Fardis (51yo)

3.6yrs

Tenure

US$9,394,600

Compensation

Dr. Maria Fardis, PhD, MBA, has been the Chief Executive Officer and President of Iovance Biotherapeutics, Inc. since June 1, 2016. Previously, Dr. Fardis held a number of key scientific and management rol ...


CEO Compensation Analysis

Compensation vs Market: Maria's total compensation ($USD9.39M) is above average for companies of similar size in the US market ($USD4.99M).

Compensation vs Earnings: Maria's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

3.0yrs

Average Tenure

57yo

Average Age

Experienced Management: IOVA's management team is considered experienced (3 years average tenure).


Board Age and Tenure

3.6yrs

Average Tenure

58.5yo

Average Age

Experienced Board: IOVA's board of directors are considered experienced (3.6 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 43.1%.


Management Team

  • Elma Hawkins (62yo)

    Advisor to the Board

    • Tenure: 3.6yrs
    • Compensation: US$3.18m
  • Tim Morris (57yo)

    CFO, Principal Accounting Officer

    • Tenure: 2.4yrs
    • Compensation: US$603.00k
  • Howard Johnson (59yo)

    Senior Vice President of Corporate Development

    • Tenure: 4.4yrs
  • Maria Fardis (51yo)

    CEO, President & Director

    • Tenure: 3.6yrs
    • Compensation: US$9.39m
  • Frederick Vogt (45yo)

    General Counsel

    • Tenure: 2.5yrs
    • Compensation: US$502.50k
  • Kelly DiTrapani

    Vice President of Medical Affairs

    • Friedrich Graf Finckenstein

      Chief Medical Officer

      • Tenure: 0.5yrs

    Board Members

    • Mario Sznol (61yo)

      Member of Scientific Advisory Board

      • Tony McPeak (83yo)

        Independent Director

        • Tenure: 8.5yrs
        • Compensation: US$561.43k
      • Michael Weiser (56yo)

        Independent Director

        • Tenure: 1.8yrs
        • Compensation: US$1.33m
      • Jeff Weber

        Member of Scientific Advisory Board

        • Patrick Hwu

          Member of Scientific Advisory Board

          • Ryan Maynard (50yo)

            Independent Director

            • Tenure: 4.9yrs
            • Compensation: US$546.43k
          • Iain Dukes (61yo)

            Chairman of the Board

            • Tenure: 3.4yrs
            • Compensation: US$1.05m
          • Jim Mulé

            Member of Scientific Advisory Board

            • Cassian Yee

              Member of Scientific Advisory Board

              • Maria Fardis (51yo)

                CEO, President & Director

                • Tenure: 3.6yrs
                • Compensation: US$9.39m

              Company Information

              Iovance Biotherapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


              Key Information

              • Name: Iovance Biotherapeutics, Inc.
              • Ticker: IOVA
              • Exchange: NasdaqGM
              • Founded: 2007
              • Industry: Biotechnology
              • Sector: Pharmaceuticals & Biotech
              • Market Cap: US$3.013b
              • Shares outstanding: 126.19m
              • Website: https://www.iovance.com

              Number of Employees


              Location

              • Iovance Biotherapeutics, Inc.
              • 999 Skyway Road
              • Suite 150
              • San Carlos
              • California
              • 94070
              • United States

              Listings

              TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
              IOVANasdaqGM (Nasdaq Global Market)YesCommon SharesUSUSDJun 2008
              2LBDB (Deutsche Boerse AG)YesCommon SharesDEEURJun 2008
              0JDKLSE (London Stock Exchange)YesCommon SharesGBUSDJun 2008

              Biography

              Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company’s lead product candidate is lifileucel, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients’ tumors for the treatment of metastatic melanoma. The company is also developing LN-145, an autologous adoptive cell therapy to treat cervical and head and neck cancers. It has collaboration agreements with Moffitt, M.D. Anderson Cancer Center, Roswell Park Cancer Institute, MedImmune, and Genocea Biosciences, Inc.; and preclinical research collaboration with the Ohio State University and with Cellectis S.A. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was founded in 2007 and is headquartered in San Carlos, California. 


              Company Analysis and Financial Data Status

              All financial data provided by Standard & Poor's Capital IQ.
              DataLast Updated (UTC time)
              Company Analysis2020/01/20 00:05
              End of Day Share Price2020/01/17 00:00
              Earnings2019/09/30
              Annual Earnings2018/12/31


              Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.